• Protection against measles and mumps in hiv-infected children
To content

Protection against measles and mumps in hiv-infected children

SOVREMENNAYA PEDIATRIYA. 2014.8(64):126–131; doi 10.15574/SP.2014.64.126

Protection against measles and mumps in hiv-infected children

Volokha A., Chernyshova L., Raus I., Demchyshina I.

Shupyk National Medical Academy of Postgraduate Education

Kiev City AIDS Center

Virology/AIDS Department of Central Epidemiology Service, Kiev, Ukraine

 

HIV-infected children are a vulnerable group for the development of vaccine-preventable infections, their frequency and severity. The study found lower levels of vaccination coverage of HIV*infected children against measles and mumps (46,5%) than in general population. Among 66 vaccinated children with HIV-infection revealed a large number of children not protected against measles (42.4%) and mumps (60.6%).The mean level of antibodies to measles and mumps was significantly lower in HIV*infected children compared with children not infected with HIV. Only 10 children (40%) with lacked antibody to measles were optimally immunized, up-to-date immunization has 23 children (56,1%) with detectable antibody. Established predictors of immune protection against measles and mumps: early start of antiretroviral therapy (in the first 24 month of age), the beginning of immunization in children on treatment of HIV-infec-tion and higher level CD4 + T cells at the time of the study. The vaccine against measles and mumps is safe for children with HIV-infection if they do not have severe immunosuppression. Additional vaccinations against measles, mumps and rubella HIV-infected children on ART who have no evidence of immune protection against these viruses may be effective in forming a protective post-vaccination immune response. Vaccination policies should be developed for HIV-infected children on HAART who lack the protective immunity against measles and mumps after up-to-date immunization.

Keywords: HIV-infected children, post-vaccination immunity, measles, mumps.

 

References:

1. Determinants of vaccine immunity in the cohort of human immunodeficiency virus-infected children living in Switzerland / Mayers C., Posfay-Barbe K. M., Aebi C. [et al.] // PIDJ. — 2009. — Vol. 28, №11. — P. 996—1001.

2. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virusinfected children / Berkelhamer S., Borock E., Elsen C. [et al.] // Clinical Infectious Diseases. — 2001. — Vol. 32. — P. 1090—1094.

3. Immunogenicity of standard-titer measles vaccine in HIV-1-Infected and uninfected zambian children: an observational study / Moss W. J, Scott S., Mugala N. [et al.] // The Journal of Infectious Diseases. — 2007. — Vol. 196. — P. 347—55.

4. Immunogenicity, immunologic memory, and safety following measles revaccination in HIV_Infected children receiving highly active antiretroviral therapy / Abzug M. J., Qin M., Levin M. [et al.] // The Journal of Infectious Diseases. — 2012. — Vol. 206. — P. 512—22.

5. Maldonado I. Measles vaccine, HIV Infection, and antiretroviral therapy — a window of opportunity / I. Maldonado // J. Infect. Dis. — 2012. — Vol. 206 (4). — P. 466—468.

6. Measles antibody in vaccinated Human Immunodeficiency Virus type 1-infected children / Arpadi S. M., Markowitz L. E., Baughman A. L. [et al.] // Pediatrics. — 1996. — Vol. 97. — P. 653.

7. Melvin A. J. Response to immunization with measles, tetanus, and Haemophilus influenza type b vaccines in children who have Human Immunodeficiency Virus type 1 infection and are treated With Highly Active Antiretroviral Therapy / A. J. Melvin, K. M. Mohan // Pediatrics. — 2003. — Vol. 111. — P. 641.

8. Moss W. J. Do children infected with HIV receiving HAART need to be revaccinated? / W. J. Moss, C. G. Sutcliff // Lancet Infect Dis. — 2010. — Vol. 10. — P. 630—4.

9. Moss W. J. Immunization of children at risk of infection with human immunodeficiency virus / W. J. Moss, C. J. Clements, N. A. Halsey // Bulletin of the World Health Organization. — 2003. — Vol. 81 (1). — P. 61—70.

10. Persistence of measles, mumps, and rubella protective antibodies 3 Years after revaccination in HIV_Infected children receiving antiretroviral therapy / Aurpibul L., Puthanakit T., Sirisanthana T., Sirisanthana V. // Clinical Infectious Diseases. — 2010. — Vol. 50 (10). — P. 1415—1418.

11. Persistent humoral immune defect in highly active antiretroviral therapytreated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection / Bekker V.,Scherpbier H., Pajkrt D. [et al.] // Pediatrics. — 2006. — Vol. 118. — P. 315.

12. Rainwater_Lovett К. Immunologic Basis for Revaccination of HIV-infected Children Receiving HAART / К. Rainwater-Lovett, W. J. Moss // Future Virology. — 2011. —Vol. 6 (1). — P. 59—71.

13. Response to measles, mumps, and rubella revaccination in HIV-Infected children with immune recovery after highly active antiretroviral therapy / Aurpibul L., Puthanakit T., Sirisanthana T., Sirisanthana V. // Clinical Infectious Diseases. — 2007. — Vol. 45. — P. 637—42.

14. Tejiokem M. C. HIV_Infected Children Living in Central Africa Have Low Persistence of Antibodies to Vaccines Used in the Expanded Program on Immunization / M. C. Tejiokem, I. Gouandjika, L. Be’niguel // PLoS ONE. — Vol. 2(12). — P. 1260.